Source comparison
PT-141 Source and Form Comparison
FDA-Registered 503B Compounding (Real Peptides) ≥98% HPLC-verified, third-party CoA, USP-grade synthesis $89–$120 18–24 months at −20°C Lyophilized powder for reconstitution, exact dosing control Highest reproducibility for research applications; verified amin
This comparison does not assign a generated winner or score.
- FDA-Registered 503B Compounding (Real Peptides)
- ≥98% HPLC-verified, third-party CoA, USP-grade synthesis
- $89–$120
- 18–24 months at −20°C
- Lyophilized powder for reconstitution, exact dosing control
- Highest reproducibility for research applications; verified amino-acid sequencing and sterility testing ensure batch-to-batch consistency critical for longitudinal studies
- Research Chemical Suppliers (Unverified)
- Variable 85–95%, often no third-party verification
- $45–$75
- Unknown, frequently unstated
- Lyophilized powder, purity uncertain
- High variability risk; absence of independent HPLC verification means stated purity is unconfirmed, leading to irreproducible results and protocol failures
- Compounded Nasal Spray (Select Clinics)
- ≥95% typical, intranasal bioavailability ~60% of subcutaneous
- $130–$180 per multi-dose unit
- 90 days refrigerated post-reconstitution
- Pre-mixed intranasal spray, fixed dosing
- Reduced bioavailability requires higher nominal doses; convenient but less precise for dose-response research due to variable nasal absorption
- Branded Vyleesi (Approved)
- >99% pharmaceutical-grade
- $950–$1100 per single-dose autoinjector
- 36 months at controlled room temperature
- Pre-filled autoinjector, 1.75mg fixed dose
- Gold standard for clinical purity but cost-prohibitive for research-scale studies; autoinjector format prevents dose titration or protocol customization
- Peptide Synthesis Labs (Custom)
- 90–98% depending on synthesis method
- $200–$350 for 10mg custom synthesis
- 12–18 months typical
- Raw powder, requires in-house quality control
- Suitable for highly specialized research requiring modifications, but demands in-house analytical chemistry capacity; synthesis quality varies significantly between labs
- The bottom line: for research requiring reproducible outcomes and verifiable material quality, FDA-registered 503B facilities like those supplying Real Peptides provide the optimal balance of purity, documentation, and cost-effectiveness. Unverified suppliers introduce uncontrolled variables that undermine study validity, while branded autoinjectors eliminate dose flexibility essential for mechanistic research.